Bullish on Cadila Pharma, Lupin, Sun Pharma: Hemang Jani, Sharekhan

In an interview with ET Now, Hemang Jani, Senior Vice President, Sharekhan, shares his views on pharma stocks. Excerpt:

ET Now: What is your view on Pharma space, particularly Aurobindo pharma?

Hemang Jani: Aurobindo has actually run up quite a lot. There is a feel that the operating profit or EBITDA number that they could report would be in the range of about Rs 525 crore, which is at least 25% higher than the market expectations of about Rs 425 crore. There might be a bit of an uptick there on the back of that.

Overall, we think that this is one space which gives a comfort in terms of their earnings quality and the margins continue to look good.

We think that selectively stocks like Cadila Pharma, which have corrected a little bit, or Sun Pharma and Lupin continue to be good investment bets.